A share price of INmune Bio Inc [INMB] is currently trading at $1.74, up 5.45%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The INMB shares have gain 16.78% over the last week, with a monthly amount drifted -4.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
INmune Bio Inc [NASDAQ: INMB] stock has seen the most recent analyst activity on July 01, 2025, when Scotiabank downgraded its rating to a Sector Underperform but kept the price target unchanged to $0.60 for it. Previously, BTIG Research downgraded its rating to Neutral on July 01, 2025. On January 28, 2025, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $23 on the stock. Alliance Global Partners started tracking the stock assigning a Buy rating and suggested a price target of $20 on October 21, 2024. Raymond James initiated its recommendation with an Outperform and recommended $18 as its price target on September 27, 2024. Scotiabank started tracking with a Sector Outperform rating for this stock on August 22, 2024, and assigned it a price target of $22. In a note dated June 01, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $16 on this stock.
INmune Bio Inc experienced fluctuations in its stock price throughout the past year between $1.38 and $11.64. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. INmune Bio Inc [NASDAQ: INMB] shares were valued at $1.74 at the most recent close of the market. An investor can expect a potential return of 1164.37% based on the average INMB price forecast.
Analyzing the INMB fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -1027.52%, Pretax Profit Margin comes in at -997.74%, and Net Profit Margin reading is -997.74%. To continue investigating profitability, this company’s Return on Assets is posted at -1.5, Equity is -1.72 and Total Capital is -1.98. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6526 points at the first support level, and at 1.5652 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7887, and for the 2nd resistance point, it is at 1.8374.
Ratios To Look Out For
To put it in perspective, the Current Ratio for INmune Bio Inc [NASDAQ:INMB] is 4.17. As well, the Quick Ratio is 4.17, while the Cash Ratio is 3.77. Considering the valuation of this stock, the price to sales ratio is 925.20, the price to book ratio is 1.82.
